Ashraf Mohammadzadeh; Ahmad shah Farhat; Ezzat Khodashenas; Jalil Tavakol Afshari; Nafiseh Pourbadakhshan; Mehdi Sohrabi
Abstract
Background: The study aimed to determine the effect of zinc consumption on cell immunity in healthy 6-year-old children. In a double-blind clinical trial after the license of parents, 40 children 6-7 years old were enrolled. The male healthy and 6-7-year-old children were included and those with chronic ...
Read More
Background: The study aimed to determine the effect of zinc consumption on cell immunity in healthy 6-year-old children. In a double-blind clinical trial after the license of parents, 40 children 6-7 years old were enrolled. The male healthy and 6-7-year-old children were included and those with chronic disease, failure to thrive, and usage of another zinc supplement in the past two months, were excluded. In the case group (N=20), twenty mg of zinc sulfate syrup has been prescribed orally for 6 months. The control group (N=20) received a placebo the same as the case group in the volume, color, bottle size, and shape. Serum zinc level and cellular proliferation were measured before intervention and 12 hours after the last dose of zinc sulfate. Zinc serum was measured by manual colorimetric method technique. A zinc level of less than 65 ug/dl is considered zinc deficiency. The lymphocyte proliferation before and after zinc treatments have been compared by paired T-test analysis. Results:The mean weight of children in the case and control group were 20.37±2.21kg and 20.92±1.98 kg respectively (P= >0.05). Serum zinc level was within the normal limit and did not differ between the two groups before and after intervention (P=0.86). After 6 months of supplementation of 20 mg zinc sulfate per day for 6 months, there were no significant improvements in Lymphocyte proliferation (with/without PHA). Conclusion: This study indicates that moderate supplementation of zinc for six months cannot efficiently improve Lymphocyte proliferation (with/without PHA) in healthy male children.
Jalil Tavakol Afshari; Mahdi Yousefi; Roshanak Salari
Abstract
Atopic dermatitis is an inflammatory skin disease that starts in the early life and usually persists by the end of life in 20% of cases. The disease shows multiple periods of relapse, and significantly affects the patient’s quality of life. The etiology of this disease is unknown, yet recent studies ...
Read More
Atopic dermatitis is an inflammatory skin disease that starts in the early life and usually persists by the end of life in 20% of cases. The disease shows multiple periods of relapse, and significantly affects the patient’s quality of life. The etiology of this disease is unknown, yet recent studies have reported incidence of immunological disorders and mutation in the filaggrin gene as the major causes. In some cases, concurrent incidence of infection with these inflammatory lesions reinforces the significance of treatment. Various methods of treatment such as emollients, corticosteroids, and calcineurin inhibitors are applied to manage this disorder. Traditional and complementary approaches may also help to control the disease. This disease is not usually easily controllable, thus requires full awareness of physicians on the underlying prospects of this disease. This review paper deals with the important aspects of the clinical perspectives and presents an integrative therapeutic approach for treating atopic dermatitis.
Zhaleh Shariati Sarabi; Jalil Tavakol Afshari; Ali Ghassemi; Mehdi Yaghobi
Abstract
The most common disease in the aged population is osteoarthritis (OA) that is resulting in progressive dysfunction following isolated cartilage injuries, subchondral bone remodeling, tissue loss, marginal osteophytes, and loss of joint space. Mesenchymal stem cells (MSCs) are multipotent stem cells; ...
Read More
The most common disease in the aged population is osteoarthritis (OA) that is resulting in progressive dysfunction following isolated cartilage injuries, subchondral bone remodeling, tissue loss, marginal osteophytes, and loss of joint space. Mesenchymal stem cells (MSCs) are multipotent stem cells; they are able to produce many or all joint tissues. Bone marrow and adipose tissue are rich sources of mesenchymal cells that are useful for the reconstruction of injured tissues such as bone, cartilage, or cardiac muscle. Recently, some studies have been performed on the use of the direct intra-articular injection of mononuclear cells (MNCs) and MSCs as potential therapeutic targets in OA. In this review, the history of MSCs in the treatment of OA are explained. Injection of Bone Marrow Aspirates Concentrate (BMAC) has significantly improved both joint pain and function in radiologic findings; some studies suggested that the injection would be even more effective in early to moderate phases of OA. Injection of MSCs in combination with growth factors may be better solution for the treatment.